UK's Competition Watchdog Targets Four Firms Over Seven-Fold Prochlorperazine Price Hike
The UK CMA alleges that four companies were involved in a non-compete agreement that resulted in a 700% increase in the cost to the NHS of a generic medicine for nausea and dizziness.
You may also be interested in...
The UK’s Competition and Markets Authority has closed “on administrative priorities grounds” its investigation into individual agreements between Alliance Pharmaceuticals, Focus Pharmaceuticals, Medreich and Lexon UK over the supply of prochlorperazine. However, an allegedly anti-competitive “overarching agreement” will continue to be investigated.
Two investigations by the UK’s Competition and Markets Authority over behaviour around prochlorperazine and nitrofurantoin have been put on hold due to the coronavirus pandemic.
The BGMA has condemned anti-competitive behavior in the UK after Aspen paid the NHS £8m in a landmark case over “illegal market sharing”.